 Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks which is decent but still underwhelming relative to the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) as a whole.Source: A 4 via Flickr
|